Pfizer Zoloft Ad Cited By FDA For Omitting Suicide Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's ad review division objects to an October print ad for the antidepressant that failed to mention the risk of suicidality and clinical worsening. The ad's brief summary referenced information from outdated labeling, the agency says.
You may also be interested in...
Pfizer's Parecoxib Ad Cited By U.K. For Using Out-Of-Date Labeling
A journal ad for parecoxib, marketed as Dynastat in the U.K., did not mention two warnings recently added to the COX-2 inhibitor for use in congestive heart failure and coronary artery bypass graft patients. The Medicines & Healthcare Products Regulatory Agency is requesting a corrective statement. The parecoxib NDA is pending at FDA.
Pfizer's Parecoxib Ad Cited By U.K. For Using Out-Of-Date Labeling
A journal ad for parecoxib, marketed as Dynastat in the U.K., did not mention two warnings recently added to the COX-2 inhibitor for use in congestive heart failure and coronary artery bypass graft patients. The Medicines & Healthcare Products Regulatory Agency is requesting a corrective statement. The parecoxib NDA is pending at FDA.
Pfizer Pulling Back “Traditional” DTC Ads, CEO McKinnell Says
The company is moving away from campaigns promoting brand awareness in favor of ads focusing on disease awareness and patient education, the Pfizer exec says. There is a “recognition” in the pharmaceutical industry that direct-to-consumer advertising needs to be reformed, McKinnell notes.